Granulomatous amoebic encephalitis medical therapy

Revision as of 14:44, 5 December 2012 by Aarti Narayan (talk | contribs)
Jump to navigation Jump to search

Granulomatous amoebic encephalitis Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Granulomatous amoebic encephalitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural history, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Case Studies

Case #1

Granulomatous amoebic encephalitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Granulomatous amoebic encephalitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Granulomatous amoebic encephalitis medical therapy

CDC on Granulomatous amoebic encephalitis medical therapy

Granulomatous amoebic encephalitis medical therapy in the news

Blogs on Granulomatous amoebic encephalitis medical therapy

Directions to Hospitals Treating Granulomatous amoebic encephalitis

Risk calculators and risk factors for Granulomatous amoebic encephalitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

GAE can, in general, must be treated by killing the pathogenic amoebas which cause it. Even with treatment, the condition is often fatal, and there are very few recorded survivors, almost all of whom suffered permanent neurocognitive deficits. Several drugs have been shown to be effective against GAE-causing organisms in vitro.[1]

Medical Therapy

Although there have been more than 200 cases of Balamuthia infection worldwide, few patients are known to have survived as a result of successful drug treatment[1,[2]]. Early diagnosis and treatment might increase the chances for survival[[3]].

Drugs used in treating Granulomatous Amebic Encephalitis (GAE) caused by Balamuthia have included a combination of flucytosine, pentamidine, fluconazole, sulfadiazine and either azithromycin or clarithromycin[1,[2],[4],5]. Recently, miltefosine in combination with some of these other drugs has shown some promise[[2]]. Much more information is needed in treating patients with GAE due to Balamuthia.

References

  1. http://path.upmc.edu/cases/case156/dx.html
  2. 2.0 2.1 2.2 Perez MT, Bush LM (2007). "Balamuthia mandrillaris amebic encephalitis". Current Infectious Disease Reports. 9 (4): 323–8. PMID 17618553. Unknown parameter |month= ignored (help)
  3. Martínez DY, Seas C, Bravo F; et al. (2010). "Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 51 (2): e7–11. doi:10.1086/653609. PMID 20550438. Unknown parameter |month= ignored (help)
  4. Siddiqui R, Khan NA (2008). "Balamuthia amoebic encephalitis: an emerging disease with fatal consequences". Microbial Pathogenesis. 44 (2): 89–97. doi:10.1016/j.micpath.2007.06.008. PMID 17913450. Unknown parameter |month= ignored (help)

5. Cary LC, Maul E, Potter C, et al. Balamuthia mandrillaris meningoencephalitis: survival of a pediatric patient. Pediatrics. Mar 2010;125(3):e699-703.

6. Drugs for Parasitic Infections: The Medical Letter; 2010.


Template:WikiDoc Sources